Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma
Journal of Clinical Oncology, 05/02/2012
Clinical Article
Janne PA et al. – Erlotinib and erlotinib plus chemotherapy have similar efficacy in clinically selected populations of patients with advanced non–small–cell lung cancer (NSCLC). EGFR mutations identify patients most likely to benefit.



